SCHEMBL894207

SCHEMBL894207

OCC1Cc2ccccc2CN1

nearest known ligand 0.69

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PNMT P11086 8/20 0.67
ADRA2A P08913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29590036 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL894205 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL29570471 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL29743356 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL4738129 1.00 PNMT (0.67) PNMTADRA2A
Hydrochloric Acid SCHEMBL7478887 0.98 PNMT (0.65) PNMTADRA2A
Hydrochloric Acid SCHEMBL7478882 0.98 PNMT (0.65) PNMTADRA2A
SCHEMBL8783405 0.85 PNMT (0.64) PNMT
SCHEMBL11388285 0.85 PNMT (0.64) PNMT
SCHEMBL8853554 0.83 PNMT (0.71) PNMTADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117586170-B Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative 江苏集萃分子工程研究院有限公司 2024-04-09 CN claimed
CN-117586170-A Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative 江苏集萃分子工程研究院有限公司 2024-02-23 CN claimed
EP-0691128-B1 Use of CRF antagonists PFIZER (US) 2002-12-11 EP claimed
US-6469041-B2 PSYCHOLOGICAL DISORDERS NEUROGEN CORPORATION 2002-10-22 US claimed
US-20020042422-A1 Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands NEUROGEN CORPORATION 2002-04-11 US claimed
US-6200979-B1 ADMINISTERING SUBSTITUTED PYRAZOLES AND PYZAZOLOPYRIMIDINES FOR TREATING PHOBIAS OBSESSIVE-COMPULSIVE DISORDER, POST-TRAUMATIC STRESS DISORDER, SINGLE EPISODE DEPRESSION, RECURRENT DEPRESSION, DYSTHYMIA, BIPOLAR DISORDERS BRIGHT GENE M (US) 2001-03-13 US claimed
EP-0674631-B1 SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS PFIZER (US) 1999-12-08 EP claimed
EP-0959074-A2 Substituted pyrazoles as CRF antagonists PFIZER INC. (US) 1999-11-24 EP claimed
EP-0941223-A1 CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-09-15 EP claimed
US-5760225-A DIAGNOSIS AND TREATMENT OF STRESS DISORDERS AND DEPRESSION NEUROGEN CORPORATION (US) 1998-06-02 US claimed
WO-1998021200-A1 CERTAIN PYRAZOLE DERIVATIVES AS CORTICOTROPIN-RELEASING FACTOR RECEPTOR CRF1 SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1998-05-22 WO claimed
US-5705646-A Substituted pyrazoles as CRF antagonists PFIZER INC. (US) 1998-01-06 US claimed
EP-0674625-B1 AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY PFIZER (US) 1997-12-10 EP claimed
EP-0764153-A1 SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY PFIZER INC. (US) 1997-03-26 EP claimed
EP-0691128-A1 Methods of administering CRF antagonists PFIZER INC. (US) 1996-01-10 EP claimed
WO-1995033727-A1 SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY PFIZER INC. (US) 1995-12-14 WO claimed
EP-0674625-A1 AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY PFIZER INC. (US) 1995-10-04 EP claimed
EP-0674631-A1 SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS PFIZER INC. (US) 1995-10-04 EP claimed
WO-1994013661-A1 SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO claimed
WO-1994013644-A1 AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY PFIZER INC. (US) 1994-06-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042422-A1 Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands CRH, CRHR1, CRHR2 PNMT 1817/4885ADRA2A 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.